Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis

Cardiovascular mortality is excessive in hemodialyzed patients. Observations in atherosclerosis suggest that endothelial dysfunction and impaired nitric oxide (NO) may be involved. However, the relation of endothelial NO to its vascular effects has not been studied conclusively in uremia. Therefore,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Society of Nephrology 2000-09, Vol.11 (9), p.1726-1734
Hauptverfasser: PASSAUER, Jens, BÜSSEMAKER, Eckhart, RANGE, Ursula, PLUG, Maria, GROSS, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1734
container_issue 9
container_start_page 1726
container_title Journal of the American Society of Nephrology
container_volume 11
creator PASSAUER, Jens
BÜSSEMAKER, Eckhart
RANGE, Ursula
PLUG, Maria
GROSS, Peter
description Cardiovascular mortality is excessive in hemodialyzed patients. Observations in atherosclerosis suggest that endothelial dysfunction and impaired nitric oxide (NO) may be involved. However, the relation of endothelial NO to its vascular effects has not been studied conclusively in uremia. Therefore, to study these questions an invasive technique was used in normotensive patients who were on hemodialysis (HD; n = 11) and in matched control subjects (n = 11). Pharmacologic agents were infused into the brachial artery to test the chain of events from NO generation to smooth muscle cell relaxation, measuring forearm blood flow by venous occlusion plethysmography. Glyceroltrinitrate (GTN 1:2.2 nmol/min; GTN 2:4.4; GTN 3:8.8), infused to establish the reaction of the vessel wall to defined doses of NO, caused a reduced response in HD patients (control subjects: 183 +/- 20 [SEM], 246 +/- 26, and 338 +/- 29%; HD patients: 161 +/- 7, 206 +/- 12, and 262 +/- 24%; baseline = 100% for each group, P: = 0.032 by ANOVA). All subsequent data were corrected for this decreased response to defined doses of NO in HD patients. L-arginine (10 mg/min), given to exclude substrate deficiency of NO synthase (NOS), caused no significant changes (control subjects: 108 +/- 4%; HD patients: 103 +/- 4%; P: = NS). Acetylcholine (ACH 1:55 nmol/min; ACH 2:110; ACH 3:220), infused to stimulate endothelial NOS, had a significantly reduced effect in HD patients (control subjects: 246 +/- 32, 340 +/- 40, and 465 +/- 52%; HD patients: 251 +/- 55, 244 +/- 36, and 318 +/- 50%; P: = 0.002). N:-monomethyl-L-arginine (LMA 1:1 micromol/min; LMA 2:2; LMA 3:4), given to block baseline NO generation, showed an enhanced response in HD patients (control subjects: 90 +/- 2, 83 +/- 2, and 74 +/- 4%; HD patients: 84 +/- 3, 73 +/- 3, and 64 +/- 4%; P: = 0.037). Vascular response to three doses of norepinephrine (60, 120, and 240 pmol/min) was comparable in both groups, which indicated similar endothelium-independent vasoconstriction. In summary, in normotensive HD patients, (1) vasodilation to defined doses of exogenous NO was reduced, (2) there was no evidence of substrate deficiency of NOS, and (3) stimulation of NOS was impaired; however, (4) baseline NO generation was increased. It is concluded that in HD patients, the NO system has a reduced capacity to regulate vascular tone and this impairment is most significant under conditions of NOS stimulation.
doi_str_mv 10.1681/ASN.V1191726
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72223605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72223605</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-51a7fe4a7e68e457679d9c4efeb599a30cd3a6baf19285db5543ef58c7ff4e133</originalsourceid><addsrcrecordid>eNpNkUtv1TAQRi0EoqWwY428QKxIseNXsqyq8pAqWPDYRo497jVK7ODJDfQ38Sfx1b0IVuPxnDOz-Ah5ztkl1x1_c_X54-U3zntuWv2AnHMlRCOkYg_rm0ndaG3EGXmC-J0xrlpjHpMzznqtZd-dk983W_SQHNCY6Ba3THGXf8Z0V3tXwCLQHOhY6xQT0BTXEh3Nv6pE7yBBsWvMidrkaZwXG8sMaT0okHxed9Xaz42HpbaHwWYx-zgdpXox5TLnFRLGDehSvyuEtM7cruRUL-1groKd7jHiU_Io2Anh2alekK9vb75cv29uP737cH112zih5Noobk0AaQ3oDqQy2vS-dxICjKrvrWDOC6tHG3jfdsqPSkkBQXXOhCCBC3FBXh33LiX_2AOuwxzRwTTZBHmPg2nbVmimKvj6CLqSEQuEYSlxtuV-4Gw4hDPUcIa_4VT8xWnvfpzB_wcf06jAyxNg0dkpFJtcxH-cYpwJLf4A4vac4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72223605</pqid></control><display><type>article</type><title>Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>PASSAUER, Jens ; BÜSSEMAKER, Eckhart ; RANGE, Ursula ; PLUG, Maria ; GROSS, Peter</creator><creatorcontrib>PASSAUER, Jens ; BÜSSEMAKER, Eckhart ; RANGE, Ursula ; PLUG, Maria ; GROSS, Peter</creatorcontrib><description>Cardiovascular mortality is excessive in hemodialyzed patients. Observations in atherosclerosis suggest that endothelial dysfunction and impaired nitric oxide (NO) may be involved. However, the relation of endothelial NO to its vascular effects has not been studied conclusively in uremia. Therefore, to study these questions an invasive technique was used in normotensive patients who were on hemodialysis (HD; n = 11) and in matched control subjects (n = 11). Pharmacologic agents were infused into the brachial artery to test the chain of events from NO generation to smooth muscle cell relaxation, measuring forearm blood flow by venous occlusion plethysmography. Glyceroltrinitrate (GTN 1:2.2 nmol/min; GTN 2:4.4; GTN 3:8.8), infused to establish the reaction of the vessel wall to defined doses of NO, caused a reduced response in HD patients (control subjects: 183 +/- 20 [SEM], 246 +/- 26, and 338 +/- 29%; HD patients: 161 +/- 7, 206 +/- 12, and 262 +/- 24%; baseline = 100% for each group, P: = 0.032 by ANOVA). All subsequent data were corrected for this decreased response to defined doses of NO in HD patients. L-arginine (10 mg/min), given to exclude substrate deficiency of NO synthase (NOS), caused no significant changes (control subjects: 108 +/- 4%; HD patients: 103 +/- 4%; P: = NS). Acetylcholine (ACH 1:55 nmol/min; ACH 2:110; ACH 3:220), infused to stimulate endothelial NOS, had a significantly reduced effect in HD patients (control subjects: 246 +/- 32, 340 +/- 40, and 465 +/- 52%; HD patients: 251 +/- 55, 244 +/- 36, and 318 +/- 50%; P: = 0.002). N:-monomethyl-L-arginine (LMA 1:1 micromol/min; LMA 2:2; LMA 3:4), given to block baseline NO generation, showed an enhanced response in HD patients (control subjects: 90 +/- 2, 83 +/- 2, and 74 +/- 4%; HD patients: 84 +/- 3, 73 +/- 3, and 64 +/- 4%; P: = 0.037). Vascular response to three doses of norepinephrine (60, 120, and 240 pmol/min) was comparable in both groups, which indicated similar endothelium-independent vasoconstriction. In summary, in normotensive HD patients, (1) vasodilation to defined doses of exogenous NO was reduced, (2) there was no evidence of substrate deficiency of NOS, and (3) stimulation of NOS was impaired; however, (4) baseline NO generation was increased. It is concluded that in HD patients, the NO system has a reduced capacity to regulate vascular tone and this impairment is most significant under conditions of NOS stimulation.</description><identifier>ISSN: 1046-6673</identifier><identifier>EISSN: 1533-3450</identifier><identifier>DOI: 10.1681/ASN.V1191726</identifier><identifier>PMID: 10966498</identifier><identifier>CODEN: JASNEU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Acetylcholine - pharmacology ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Pressure ; Emergency and intensive care: renal failure. Dialysis management ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Female ; Forearm - blood supply ; Humans ; Intensive care medicine ; Male ; Medical sciences ; Nitric Oxide - biosynthesis ; Nitric Oxide - pharmacology ; Nitric Oxide Synthase - metabolism ; Nitric Oxide Synthase Type III ; Nitroglycerin - pharmacology ; Norepinephrine - pharmacology ; omega-N-Methylarginine - pharmacology ; Reference Values ; Regional Blood Flow - drug effects ; Renal Dialysis - adverse effects ; Time Factors ; Vasodilation</subject><ispartof>Journal of the American Society of Nephrology, 2000-09, Vol.11 (9), p.1726-1734</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-51a7fe4a7e68e457679d9c4efeb599a30cd3a6baf19285db5543ef58c7ff4e133</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1501036$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10966498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PASSAUER, Jens</creatorcontrib><creatorcontrib>BÜSSEMAKER, Eckhart</creatorcontrib><creatorcontrib>RANGE, Ursula</creatorcontrib><creatorcontrib>PLUG, Maria</creatorcontrib><creatorcontrib>GROSS, Peter</creatorcontrib><title>Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis</title><title>Journal of the American Society of Nephrology</title><addtitle>J Am Soc Nephrol</addtitle><description>Cardiovascular mortality is excessive in hemodialyzed patients. Observations in atherosclerosis suggest that endothelial dysfunction and impaired nitric oxide (NO) may be involved. However, the relation of endothelial NO to its vascular effects has not been studied conclusively in uremia. Therefore, to study these questions an invasive technique was used in normotensive patients who were on hemodialysis (HD; n = 11) and in matched control subjects (n = 11). Pharmacologic agents were infused into the brachial artery to test the chain of events from NO generation to smooth muscle cell relaxation, measuring forearm blood flow by venous occlusion plethysmography. Glyceroltrinitrate (GTN 1:2.2 nmol/min; GTN 2:4.4; GTN 3:8.8), infused to establish the reaction of the vessel wall to defined doses of NO, caused a reduced response in HD patients (control subjects: 183 +/- 20 [SEM], 246 +/- 26, and 338 +/- 29%; HD patients: 161 +/- 7, 206 +/- 12, and 262 +/- 24%; baseline = 100% for each group, P: = 0.032 by ANOVA). All subsequent data were corrected for this decreased response to defined doses of NO in HD patients. L-arginine (10 mg/min), given to exclude substrate deficiency of NO synthase (NOS), caused no significant changes (control subjects: 108 +/- 4%; HD patients: 103 +/- 4%; P: = NS). Acetylcholine (ACH 1:55 nmol/min; ACH 2:110; ACH 3:220), infused to stimulate endothelial NOS, had a significantly reduced effect in HD patients (control subjects: 246 +/- 32, 340 +/- 40, and 465 +/- 52%; HD patients: 251 +/- 55, 244 +/- 36, and 318 +/- 50%; P: = 0.002). N:-monomethyl-L-arginine (LMA 1:1 micromol/min; LMA 2:2; LMA 3:4), given to block baseline NO generation, showed an enhanced response in HD patients (control subjects: 90 +/- 2, 83 +/- 2, and 74 +/- 4%; HD patients: 84 +/- 3, 73 +/- 3, and 64 +/- 4%; P: = 0.037). Vascular response to three doses of norepinephrine (60, 120, and 240 pmol/min) was comparable in both groups, which indicated similar endothelium-independent vasoconstriction. In summary, in normotensive HD patients, (1) vasodilation to defined doses of exogenous NO was reduced, (2) there was no evidence of substrate deficiency of NOS, and (3) stimulation of NOS was impaired; however, (4) baseline NO generation was increased. It is concluded that in HD patients, the NO system has a reduced capacity to regulate vascular tone and this impairment is most significant under conditions of NOS stimulation.</description><subject>Acetylcholine - pharmacology</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Forearm - blood supply</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide - pharmacology</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Nitric Oxide Synthase Type III</subject><subject>Nitroglycerin - pharmacology</subject><subject>Norepinephrine - pharmacology</subject><subject>omega-N-Methylarginine - pharmacology</subject><subject>Reference Values</subject><subject>Regional Blood Flow - drug effects</subject><subject>Renal Dialysis - adverse effects</subject><subject>Time Factors</subject><subject>Vasodilation</subject><issn>1046-6673</issn><issn>1533-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkUtv1TAQRi0EoqWwY428QKxIseNXsqyq8pAqWPDYRo497jVK7ODJDfQ38Sfx1b0IVuPxnDOz-Ah5ztkl1x1_c_X54-U3zntuWv2AnHMlRCOkYg_rm0ndaG3EGXmC-J0xrlpjHpMzznqtZd-dk983W_SQHNCY6Ba3THGXf8Z0V3tXwCLQHOhY6xQT0BTXEh3Nv6pE7yBBsWvMidrkaZwXG8sMaT0okHxed9Xaz42HpbaHwWYx-zgdpXox5TLnFRLGDehSvyuEtM7cruRUL-1groKd7jHiU_Io2Anh2alekK9vb75cv29uP737cH112zih5Noobk0AaQ3oDqQy2vS-dxICjKrvrWDOC6tHG3jfdsqPSkkBQXXOhCCBC3FBXh33LiX_2AOuwxzRwTTZBHmPg2nbVmimKvj6CLqSEQuEYSlxtuV-4Gw4hDPUcIa_4VT8xWnvfpzB_wcf06jAyxNg0dkpFJtcxH-cYpwJLf4A4vac4Q</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>PASSAUER, Jens</creator><creator>BÜSSEMAKER, Eckhart</creator><creator>RANGE, Ursula</creator><creator>PLUG, Maria</creator><creator>GROSS, Peter</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis</title><author>PASSAUER, Jens ; BÜSSEMAKER, Eckhart ; RANGE, Ursula ; PLUG, Maria ; GROSS, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-51a7fe4a7e68e457679d9c4efeb599a30cd3a6baf19285db5543ef58c7ff4e133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acetylcholine - pharmacology</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Forearm - blood supply</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide - pharmacology</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Nitric Oxide Synthase Type III</topic><topic>Nitroglycerin - pharmacology</topic><topic>Norepinephrine - pharmacology</topic><topic>omega-N-Methylarginine - pharmacology</topic><topic>Reference Values</topic><topic>Regional Blood Flow - drug effects</topic><topic>Renal Dialysis - adverse effects</topic><topic>Time Factors</topic><topic>Vasodilation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PASSAUER, Jens</creatorcontrib><creatorcontrib>BÜSSEMAKER, Eckhart</creatorcontrib><creatorcontrib>RANGE, Ursula</creatorcontrib><creatorcontrib>PLUG, Maria</creatorcontrib><creatorcontrib>GROSS, Peter</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PASSAUER, Jens</au><au>BÜSSEMAKER, Eckhart</au><au>RANGE, Ursula</au><au>PLUG, Maria</au><au>GROSS, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis</atitle><jtitle>Journal of the American Society of Nephrology</jtitle><addtitle>J Am Soc Nephrol</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>11</volume><issue>9</issue><spage>1726</spage><epage>1734</epage><pages>1726-1734</pages><issn>1046-6673</issn><eissn>1533-3450</eissn><coden>JASNEU</coden><abstract>Cardiovascular mortality is excessive in hemodialyzed patients. Observations in atherosclerosis suggest that endothelial dysfunction and impaired nitric oxide (NO) may be involved. However, the relation of endothelial NO to its vascular effects has not been studied conclusively in uremia. Therefore, to study these questions an invasive technique was used in normotensive patients who were on hemodialysis (HD; n = 11) and in matched control subjects (n = 11). Pharmacologic agents were infused into the brachial artery to test the chain of events from NO generation to smooth muscle cell relaxation, measuring forearm blood flow by venous occlusion plethysmography. Glyceroltrinitrate (GTN 1:2.2 nmol/min; GTN 2:4.4; GTN 3:8.8), infused to establish the reaction of the vessel wall to defined doses of NO, caused a reduced response in HD patients (control subjects: 183 +/- 20 [SEM], 246 +/- 26, and 338 +/- 29%; HD patients: 161 +/- 7, 206 +/- 12, and 262 +/- 24%; baseline = 100% for each group, P: = 0.032 by ANOVA). All subsequent data were corrected for this decreased response to defined doses of NO in HD patients. L-arginine (10 mg/min), given to exclude substrate deficiency of NO synthase (NOS), caused no significant changes (control subjects: 108 +/- 4%; HD patients: 103 +/- 4%; P: = NS). Acetylcholine (ACH 1:55 nmol/min; ACH 2:110; ACH 3:220), infused to stimulate endothelial NOS, had a significantly reduced effect in HD patients (control subjects: 246 +/- 32, 340 +/- 40, and 465 +/- 52%; HD patients: 251 +/- 55, 244 +/- 36, and 318 +/- 50%; P: = 0.002). N:-monomethyl-L-arginine (LMA 1:1 micromol/min; LMA 2:2; LMA 3:4), given to block baseline NO generation, showed an enhanced response in HD patients (control subjects: 90 +/- 2, 83 +/- 2, and 74 +/- 4%; HD patients: 84 +/- 3, 73 +/- 3, and 64 +/- 4%; P: = 0.037). Vascular response to three doses of norepinephrine (60, 120, and 240 pmol/min) was comparable in both groups, which indicated similar endothelium-independent vasoconstriction. In summary, in normotensive HD patients, (1) vasodilation to defined doses of exogenous NO was reduced, (2) there was no evidence of substrate deficiency of NOS, and (3) stimulation of NOS was impaired; however, (4) baseline NO generation was increased. It is concluded that in HD patients, the NO system has a reduced capacity to regulate vascular tone and this impairment is most significant under conditions of NOS stimulation.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>10966498</pmid><doi>10.1681/ASN.V1191726</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1046-6673
ispartof Journal of the American Society of Nephrology, 2000-09, Vol.11 (9), p.1726-1734
issn 1046-6673
1533-3450
language eng
recordid cdi_proquest_miscellaneous_72223605
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Acetylcholine - pharmacology
Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood Pressure
Emergency and intensive care: renal failure. Dialysis management
Endothelium, Vascular - drug effects
Endothelium, Vascular - physiopathology
Female
Forearm - blood supply
Humans
Intensive care medicine
Male
Medical sciences
Nitric Oxide - biosynthesis
Nitric Oxide - pharmacology
Nitric Oxide Synthase - metabolism
Nitric Oxide Synthase Type III
Nitroglycerin - pharmacology
Norepinephrine - pharmacology
omega-N-Methylarginine - pharmacology
Reference Values
Regional Blood Flow - drug effects
Renal Dialysis - adverse effects
Time Factors
Vasodilation
title Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A33%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20in%20vivo%20showing%20increase%20of%20baseline%20nitric%20oxide%20generation%20and%20impairment%20of%20endothelium-dependent%20vasodilation%20in%20normotensive%20patients%20on%20chronic%20hemodialysis&rft.jtitle=Journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=PASSAUER,%20Jens&rft.date=2000-09-01&rft.volume=11&rft.issue=9&rft.spage=1726&rft.epage=1734&rft.pages=1726-1734&rft.issn=1046-6673&rft.eissn=1533-3450&rft.coden=JASNEU&rft_id=info:doi/10.1681/ASN.V1191726&rft_dat=%3Cproquest_cross%3E72223605%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72223605&rft_id=info:pmid/10966498&rfr_iscdi=true